Sign In
Buy RA
$12.81
+0.0400 (+0.313%)
At Close: Jul 31, 2026
LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
10:00am, Monday, 27'th Jul 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist
RA: A Classic Fixed-Income CEF In 'Real Assets' Clothing
04:10am, Monday, 27'th Jul 2026
Brookfield Real Assets Income Fund is a fixed income CEF, not a direct real assets holder, despite its name. RA primarily invests in corporate and securitized credit, with only 7.9% in equities and no
Brookfield Real Assets Income Fund (NYSE:RA) Shares Cross Above 200 Day Moving Average – Here’s Why
02:41am, Thursday, 23'rd Jul 2026
Brookfield Real Assets Income Fund Inc. (NYSE: RA - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.9
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Brookfield Real Assets Income Fund Inc. Declares Q3 2026 Distribution Schedule
04:58pm, Friday, 26'th Jun 2026
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund's monthl
Brookfield Real Assets Income Fund Inc. Announces Portfolio Management Team Change
01:19pm, Monday, 08'th Jun 2026
NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (the “Fund”) (NYSE: RA) today announced upcoming portfolio management changes at Oaktree Fund Advisors, LLC (“
Organon to Present New Research on Access and Value at ISPOR 2026
08:00am, Friday, 15'th May 2026
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data acros
RA: NAV Erosion Will Continue Even When Interest Rates Decline
09:15pm, Thursday, 23'rd Apr 2026
Brookfield Real Assets Income Fund maintains a high 10.9% yield but suffers from persistent NAV erosion due to unsustainable dividend payouts. RA's net investment income consistently fails to cover di
Brookfield Real Assets Income Fund Inc. Declares Q2 2026 Distribution Schedule
05:15pm, Friday, 27'th Mar 2026
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund's month
Brookfield Real Assets Income Fund Inc. Announces Portfolio Management Team Change
04:06pm, Friday, 06'th Mar 2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Brookfield Public Securities Group LLC today announced an upcoming change to the Brookfield Real Assets Income Fund Inc. (the “Fund”) (NYSE: RA) portfo
Brookfield Real Assets Income Fund Inc. $RA Position Increased by Penserra Capital Management LLC
04:40am, Friday, 06'th Feb 2026
Penserra Capital Management LLC increased its holdings in Brookfield Real Assets Income Fund Inc. (NYSE: RA) by 21.7% in the undefined quarter, according to its most recent 13F filing with the SEC. Th
RA: 10% Yield Not As Good As It Looks
09:39am, Wednesday, 28'th Jan 2026
Brookfield Real Assets Income Fund offers a tempting 10.88% yield but faces structural weaknesses, leading me to rate it Hold. RA's portfolio is heavily leveraged and concentrated in below-investment-
FMB WEALTH MANAGEMENT Buys 5,592 Shares of AnaptysBio Inc (ANAB)
09:12am, Thursday, 22'nd Jan 2026
Summary FMB WEALTH MANAGEMENT initiated a new position in AnaptysBio Inc(ANAB), purchasing 5,592 shares valued at approximately $271,100 as of its late
Brookfield Real Assets Income Fund Inc. Declares Q1 2026 Distribution Schedule
04:35pm, Friday, 26'th Dec 2025
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund's monthl
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovati
